APP
EW icon

Alpha Paradigm Partners’s Edwards Lifesciences EW Stock Holding History

Alpha Paradigm Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,495
Closed -$194K – 589
2021
Q4 		$194K Buy
+1,495
New +$174K 0.08% 347
2021
Q1 		– Sell
-894
Closed -$82K – 541
2020
Q4 		$82K Buy
+894
New +$74.2K 0.03% 329

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alpha Paradigm Partners's EW Position: Q1 2022 in Review

Alpha Paradigm Partners sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 1,495 shares — an estimated $194K sold.

Alpha Paradigm Partners first reported a position in EW in Q4 2020 and held it in 2 quarters. The position peaked at $194K in Q4 2021. 1,312 funds tracked by Wall St. Rank hold EW as of Q1 2022.

  • Alpha Paradigm Partners reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 1,495 Edwards Lifesciences shares in Q1 2022, an estimated $194K.
  • Alpha Paradigm Partners first reported a position in Edwards Lifesciences in Q4 2020 and held it in 2 quarters.
  • Alpha Paradigm Partners's Edwards Lifesciences position peaked at $194K in Q4 2021.
  • 1,312 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Alpha Paradigm Partners's 13F filing for Q1 2022, filed 16 May 2022.